

Dedee Murrell

List of Publications by Citations

Source: <https://exaly.com/author-pdf/8603576/dedee-murrell-publications-by-citations.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

213
papers

6,342
citations

42
h-index

76
g-index

299
ext. papers

7,880
ext. citations

3.2
avg, IF

5.91
L-index

#	Paper	IF	Citations
213	The classification of inherited epidermolysis bullosa (EB): Report of the Third International Consensus Meeting on Diagnosis and Classification of EB. <i>Journal of the American Academy of Dermatology</i> , 2008 , 58, 931-50	4.5	690
212	Inherited epidermolysis bullosa: updated recommendations on diagnosis and classification. <i>Journal of the American Academy of Dermatology</i> , 2014 , 70, 1103-26	4.5	596
211	Consensus statement on definitions of disease, end points, and therapeutic response for pemphigus. <i>Journal of the American Academy of Dermatology</i> , 2008 , 58, 1043-6	4.5	372
210	Definitions and outcome measures for bullous pemphigoid: recommendations by an international panel of experts. <i>Journal of the American Academy of Dermatology</i> , 2012 , 66, 479-85	4.5	203
209	Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study. <i>BMC Cancer</i> , 2017 , 17, 332	4.8	196
208	Consensus reclassification of inherited epidermolysis bullosa and other disorders with skin fragility. <i>British Journal of Dermatology</i> , 2020 , 183, 614-627	4	179
207	A clinical study comparing methyl aminolevulinate photodynamic therapy and surgery in small superficial basal cell carcinoma (8-20 mm), with a 12-month follow-up. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2008 , 22, 1302-11	4.6	163
206	Reliability and convergent validity of two outcome instruments for pemphigus. <i>Journal of Investigative Dermatology</i> , 2009 , 129, 2404-10	4.3	149
205	Towards global consensus on outcome measures for atopic eczema research: results of the HOME II meeting. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2012 , 67, 1111-7	9.3	137
204	Diagnosis and management of pemphigus: Recommendations of an international panel of experts. <i>Journal of the American Academy of Dermatology</i> , 2020 , 82, 575-585.e1	4.5	127
203	Should biologics for psoriasis be interrupted in the era of COVID-19?. <i>Journal of the American Academy of Dermatology</i> , 2020 , 82, 1217-1218	4.5	119
202	Risk of lymphoma in patients with atopic dermatitis and the role of topical treatment: A systematic review and meta-analysis. <i>Journal of the American Academy of Dermatology</i> , 2015 , 72, 992-1002	4.5	118
201	Laminin 5 mutations in junctional epidermolysis bullosa: molecular basis of Herlitz vs. non-Herlitz phenotypes. <i>Human Genetics</i> , 2002 , 110, 41-51	6.3	111
200	Phase 2B randomized study of nemolizumab in adults with moderate-to-severe atopic dermatitis and severe pruritus. <i>Journal of Allergy and Clinical Immunology</i> , 2020 , 145, 173-182	11.5	108
199	A systematic review of randomized controlled trials for pemphigus vulgaris and pemphigus foliaceus. <i>Journal of the American Academy of Dermatology</i> , 2011 , 64, 903-8	4.5	100
198	Inherited epidermolysis bullosa: new diagnostic criteria and classification. <i>Clinics in Dermatology</i> , 2012 , 30, 70-7	3	99
197	Autoimmune Subepidermal Bullous Diseases of the Skin and Mucosae: Clinical Features, Diagnosis, and Management. <i>Clinical Reviews in Allergy and Immunology</i> , 2018 , 54, 26-51	12.3	94

196	Definitions and outcome measures for mucous membrane pemphigoid: recommendations of an international panel of experts. <i>Journal of the American Academy of Dermatology</i> , 2015 , 72, 168-74	4.5	93
195	Report from the fourth international consensus meeting to harmonize core outcome measures for atopic eczema/dermatitis clinical trials (HOME initiative). <i>British Journal of Dermatology</i> , 2016 , 175, 69-74	4	90
194	Fibroblast-derived dermal matrix drives development of aggressive cutaneous squamous cell carcinoma in patients with recessive dystrophic epidermolysis bullosa. <i>Cancer Research</i> , 2012 , 72, 3522-34	10.1	83
193	Development of a Glucocorticoid Toxicity Index (GTI) using multicriteria decision analysis. <i>Annals of the Rheumatic Diseases</i> , 2017 , 76, 543-546	2.4	80
192	Innate sensing of microbial products promotes wound-induced skin cancer. <i>Nature Communications</i> , 2015 , 6, 5932	17.4	80
191	A phase II randomized vehicle-controlled trial of intradermal allogeneic fibroblasts for recessive dystrophic epidermolysis bullosa. <i>Journal of the American Academy of Dermatology</i> , 2013 , 69, 898-908.e7	4.5	78
190	Quality of life evaluation in epidermolysis bullosa (EB) through the development of the QOLEB questionnaire: an EB-specific quality of life instrument. <i>British Journal of Dermatology</i> , 2009 , 161, 1323-30	4	76
189	Epidermolysis bullosa with congenital pyloric atresia: novel mutations in the beta 4 integrin gene (ITGB4) and genotype/phenotype correlations. <i>Pediatric Research</i> , 2001 , 49, 618-26	3.2	76
188	Use of systemic corticosteroids for atopic dermatitis: International Eczema Council consensus statement. <i>British Journal of Dermatology</i> , 2018 , 178, 768-775	4	71
187	Management of cutaneous squamous cell carcinoma in patients with epidermolysis bullosa: best clinical practice guidelines. <i>British Journal of Dermatology</i> , 2016 , 174, 56-67	4	70
186	Autoantibodies to type VII collagen recognize epitopes in a fibronectin-like region of the noncollagenous (NC1) domain. <i>Journal of Investigative Dermatology</i> , 1993 , 100, 618-22	4.3	70
185	Interventions for pemphigus vulgaris and pemphigus foliaceus. <i>The Cochrane Library</i> , 2009 , CD006263	5.2	68
184	Updated S2K guidelines on the management of pemphigus vulgaris and foliaceus initiated by the european academy of dermatology and venereology (EADV). <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020 , 34, 1900-1913	4.6	60
183	Epidemiology of epidermolysis bullosa in the antipodes: the Australasian Epidermolysis Bullosa Registry with a focus on Herlitz junctional epidermolysis bullosa. <i>Archives of Dermatology</i> , 2010 , 146, 635-40		57
182	APOBEC mutation drives early-onset squamous cell carcinomas in recessive dystrophic epidermolysis bullosa. <i>Science Translational Medicine</i> , 2018 , 10,	17.5	53
181	Development of a quality-of-life instrument for autoimmune bullous disease: the Autoimmune Bullous Disease Quality of Life questionnaire. <i>JAMA Dermatology</i> , 2013 , 149, 1186-91	5.1	52
180	A randomized controlled trial of pimecrolimus cream 1% in adolescents and adults with head and neck atopic dermatitis and intolerant of, or dependent on, topical corticosteroids. <i>British Journal of Dermatology</i> , 2007 , 157, 954-9	4	52
179	Calculation of cut-off values based on the Autoimmune Bullous Skin Disorder Intensity Score (ABSIS) and Pemphigus Disease Area Index (PDAI) pemphigus scoring systems for defining moderate, significant and extensive types of pemphigus. <i>British Journal of Dermatology</i> , 2016 , 175, 142-9	4	52

178	A comparative study between transmission electron microscopy and immunofluorescence mapping in the diagnosis of epidermolysis bullosa. <i>American Journal of Dermatopathology</i> , 2006 , 28, 387-94	0.9	51
177	Suppression of TGF β and Angiogenesis by Type VII Collagen in Cutaneous SCC. <i>Journal of the National Cancer Institute</i> , 2016 , 108,	9.7	48
176	Oral pimecrolimus in the treatment of moderate to severe chronic plaque-type psoriasis: a double-blind, multicentre, randomized, dose-finding trial. <i>British Journal of Dermatology</i> , 2005 , 152, 1214-27	4.27	44
175	The development and validation of the treatment of autoimmune bullous disease quality of life questionnaire, a tool to measure the quality of life impacts of treatments used in patients with autoimmune blistering disease. <i>British Journal of Dermatology</i> , 2013 , 169, 1000-6	4	43
174	Diagnosis and clinical features of pemphigus vulgaris. <i>Dermatologic Clinics</i> , 2011 , 29, 373-80, vii	4.2	43
173	Treatment considerations for patients with pemphigus during the COVID-19 pandemic. <i>Journal of the American Academy of Dermatology</i> , 2020 , 82, e235-e236	4.5	42
172	Consensus recommendations on the use of daylight photodynamic therapy with methyl aminolevulinate cream for actinic keratoses in Australia. <i>Australasian Journal of Dermatology</i> , 2016 , 57, 167-74	1.3	42
171	The challenges of living with and managing epidermolysis bullosa: insights from patients and caregivers. <i>Orphanet Journal of Rare Diseases</i> , 2020 , 15, 1	4.2	41
170	Development, reliability, and validity of a novel Epidermolysis Bullosa Disease Activity and Scarring Index (EBDASI). <i>Journal of the American Academy of Dermatology</i> , 2014 , 70, 89-97.e1-13	4.5	37
169	International Bullous Diseases Group: consensus on diagnostic criteria for epidermolysis bullosa acquisita. <i>British Journal of Dermatology</i> , 2018 , 179, 30-41	4	35
168	Large International Validation of ABSIS and PDAI Pemphigus Severity Scores. <i>Journal of Investigative Dermatology</i> , 2019 , 139, 31-37	4.3	33
167	Interventions for mucous membrane pemphigoid and epidermolysis bullosa acquisita. <i>The Cochrane Library</i> , 2003 , CD004056	5.2	32
166	How to take skin biopsies for epidermolysis bullosa. <i>Dermatologic Clinics</i> , 2010 , 28, 197-200, vii	4.2	31
165	Clinical heterogeneity in recessive epidermolysis bullosa due to mutations in the keratin 14 gene, KRT14. <i>Clinical and Experimental Dermatology</i> , 2008 , 33, 689-97	1.8	30
164	Review of autoimmune blistering diseases: the Pemphigoid diseases. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019 , 33, 1685-1694	4.6	29
163	Evidence-based management of bullous pemphigoid. <i>Dermatologic Clinics</i> , 2011 , 29, 613-20	4.2	27
162	A pilot comparison study of four clinician-rated atopic dermatitis severity scales. <i>British Journal of Dermatology</i> , 2015 , 173, 488-97	4	26
161	Outcome measures for autoimmune blistering diseases. <i>Journal of Dermatology</i> , 2015 , 42, 31-6	1.6	24

160	Diagnosis and clinical features of pemphigus vulgaris. <i>Immunology and Allergy Clinics of North America</i> , 2012 , 32, 233-43, v-vi	3.3	24
159	Quality of life measurements in epidermolysis bullosa: tools for clinical research and patient care. <i>Dermatologic Clinics</i> , 2010 , 28, 185-90	4.2	22
158	A comparison study of clinician-rated atopic dermatitis outcome measures for intermediate- to dark-skinned patients. <i>British Journal of Dermatology</i> , 2017 , 176, 985-992	4	21
157	The Reliability, Validity and Responsiveness of Two Disease Scores (BPDAl and ABSIS) for Bullous Pemphigoid: Which One to Use?. <i>Acta Dermato-Venereologica</i> , 2017 , 97, 24-31	2.2	21
156	A quantitative approach to histopathological dissection of elastin-related disorders using multiphoton microscopy. <i>British Journal of Dermatology</i> , 2013 , 169, 869-79	4	21
155	Reliability of the autoimmune bullous disease quality of life (ABQOL) questionnaire in the USA. <i>Quality of Life Research</i> , 2015 , 24, 2257-60	3.7	20
154	Cytoskeletal protein Flightless I inhibits apoptosis, enhances tumor cell invasion and promotes cutaneous squamous cell carcinoma progression. <i>Oncotarget</i> , 2015 , 6, 36426-40	3.3	20
153	Age and etiology of childhood epidermolysis bullosa mortality. <i>Journal of Dermatological Treatment</i> , 2015 , 26, 178-82	2.8	19
152	Measuring of quality of life in autoimmune blistering disorders in Poland. Validation of disease-specific Autoimmune Bullous Disease Quality of Life (ABQOL) and the Treatment Autoimmune Bullous Disease Quality of Life (TABQOL) questionnaires. <i>Advances in Medical Sciences</i> , 2017 , 62, 92-96	2.8	18
151	Health-related quality of life in epidermolysis bullosa: Validation of the Dutch QOLEB questionnaire and assessment in the Dutch population. <i>Acta Dermato-Venereologica</i> , 2014 , 94, 442-7	2.2	17
150	Infection and infection prevention in patients treated with immunosuppressive medications for autoimmune bullous disorders. <i>Dermatologic Clinics</i> , 2011 , 29, 591-8	4.2	17
149	Alopecia in epidermolysis bullosa. <i>Dermatologic Clinics</i> , 2010 , 28, 165-9	4.2	17
148	Translation, cross-cultural adaptation and validation of the Quality of Life Evaluation in Epidermolysis Bullosa instrument in Brazilian Portuguese. <i>International Journal of Dermatology</i> , 2016 , 55, e94-9	1.7	16
147	European Guidelines (S3) on diagnosis and management of mucous membrane pemphigoid, initiated by the European Academy of Dermatology and Venereology - Part II. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021 , 35, 1926-1948	4.6	16
146	Update on the pathogenesis of squamous cell carcinoma development in recessive dystrophic epidermolysis bullosa. <i>European Journal of Dermatology</i> , 2015 , 25 Suppl 1, 30-2	0.8	15
145	Use of cetuximab as an adjuvant agent to radiotherapy and surgery in recessive dystrophic epidermolysis bullosa with squamous cell carcinoma. <i>British Journal of Dermatology</i> , 2013 , 169, 208-10	4	15
144	Treatment of pemphigus: the need for more evidence. <i>Archives of Dermatology</i> , 2008 , 144, 100-1		15
143	Updated international expert recommendations for the management of autoimmune bullous diseases during the COVID-19 pandemic. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021 , 35, e412-e414	4.6	15

142	Validation of the BIOCHIP test for the diagnosis of bullous pemphigoid, pemphigus vulgaris and pemphigus foliaceus. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020 , 34, 153-160	4.6	15
141	Perspective From the 5th International Pemphigus and Pemphigoid Foundation Scientific Conference. <i>Frontiers in Medicine</i> , 2018 , 5, 306	4.9	15
140	Prevalence of anemia in patients with epidermolysis bullosa registered in Australia. <i>International Journal of Women's Dermatology</i> , 2015 , 1, 37-40	2	14
139	The Epidermolysis Bullosa Disease Activity and Scarring Index (EBDASI): grading disease severity and assessing responsiveness to clinical change in epidermolysis bullosa. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017 , 31, 692-698	4.6	13
138	Hair loss in autoimmune cutaneous bullous disorders. <i>Dermatologic Clinics</i> , 2011 , 29, 503-9, xi	4.2	13
137	Proof of concept for the clinical effects of oral rilzabrutinib, the first Bruton tyrosine kinase inhibitor for pemphigus vulgaris: the phase II BELIEVE study. <i>British Journal of Dermatology</i> , 2021 , 185, 745-755	4	13
136	Epidermolysis bullosa in Australia and New Zealand. <i>Dermatologic Clinics</i> , 2010 , 28, 433-8, xvi	4.2	12
135	A review of case-control studies on the risk factors for the development of autoimmune blistering diseases. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2016 , 30, 595-603	4.6	10
134	Update on COVID-19 effects in dermatology specialty. <i>Dermatologic Therapy</i> , 2020 , 33, e13523	2.2	10
133	Management of pemphigus. <i>F1000prime Reports</i> , 2014 , 6, 32		10
132	The reliability and validity of outcome measures for atopic dermatitis in patients with pigmented skin: A grey area. <i>International Journal of Women's Dermatology</i> , 2015 , 1, 150-154	2	10
131	European guidelines (S3) on diagnosis and management of mucous membrane pemphigoid, initiated by the European Academy of Dermatology and Venereology - Part I. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021 , 35, 1750-1764	4.6	10
130	Advances in understanding and managing bullous pemphigoid. <i>F1000Research</i> , 2015 , 4,	3.6	9
129	Mucous membrane pemphigoid: are laminin 5 antibodies a risk factor for laryngeal involvement?. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2009 , 23, 169-70	4.6	9
128	Efficacy of a Bruton's Tyrosine Kinase Inhibitor (PRN-473) in the treatment of canine pemphigus foliaceus. <i>Veterinary Dermatology</i> , 2020 , 31, 291-e71	1.8	9
127	Nemolizumab is associated with a rapid improvement in atopic dermatitis signs and symptoms: subpopulation (EASI ≥ 6) analysis of randomized phase 2B study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021 , 35, 1562-1568	4.6	9
126	Marked intrafamilial phenotypic heterogeneity in dystrophic epidermolysis bullosa caused by inheritance of a mild dominant glycine substitution and a novel deep intronic recessive COL7A1 mutation. <i>British Journal of Dermatology</i> , 2016 , 174, 1122-5	4	9
125	A dermatologist's perspective of the COVID-19 outbreak. <i>Dermatologic Therapy</i> , 2020 , 33, e13538	2.2	8

124	A review of scoring systems for ocular involvement in chronic cutaneous bullous diseases. <i>Orphanet Journal of Rare Diseases</i> , 2018 , 13, 83	4.2	8
123	Reliability and validity of the Chinese version of the autoimmune bullous disease quality of life (ABQOL) questionnaire. <i>Health and Quality of Life Outcomes</i> , 2017 , 15, 31	3	8
122	Outcomes of 11 pregnancies in three patients with recessive forms of epidermolysis bullosa. <i>British Journal of Dermatology</i> , 2011 , 165, 700-1	4	8
121	Naevus of Ota presenting in two generations: a mother and daughter. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2009 , 23, 102-4	4.6	8
120	Patient-reported outcomes and quality of life in recessive dystrophic epidermolysis bullosa: A global cross-sectional survey. <i>Journal of the American Academy of Dermatology</i> , 2021 , 85, 1161-1167	4.5	8
119	Secukinumab lowers expression of ACE2 in affected skin of patients with psoriasis. <i>Journal of Allergy and Clinical Immunology</i> , 2021 , 147, 1107-1109.e2	11.5	8
118	What is novel in the clinical management of pemphigus. <i>Expert Review of Clinical Pharmacology</i> , 2019 , 12, 973-980	3.8	7
117	Autoimmune Bullous Disease Quality of Life (ABQoL) questionnaire: Validation of the translated Persian version in pemphigus vulgaris. <i>International Journal of Women's Dermatology</i> , 2020 , 6, 306-310	2	7
116	Quality of Life in Greek Patients with Autoimmune Bullous Diseases Assessed with ABQOL and TABQOL Indexes. <i>Acta Dermato-Venereologica</i> , 2017 , 97, 1145-1147	2.2	7
115	Clinical application of a molecular assay for the detection of dermatophytosis and a novel non-invasive sampling technique. <i>Pathology</i> , 2016 , 48, 720-726	1.6	7
114	Digenic inheritance in epidermolysis bullosa simplex involving two novel mutations in KRT5 and KRT14. <i>British Journal of Dermatology</i> , 2017 , 177, 262-264	4	7
113	Where do we stand as dermatologists in combat with COVID-19. <i>Dermatologic Therapy</i> , 2020 , 33, e1363&.2		7
112	Open trial of Bruton's tyrosine kinase inhibitor (PRN1008) in the treatment of canine pemphigus foliaceus. <i>Veterinary Dermatology</i> , 2020 , 31, 410-e110	1.8	7
111	Subepithelial autoimmune blistering dermatoses: Clinical features and diagnosis. <i>Journal of the American Academy of Dermatology</i> , 2021 , 85, 1-14	4.5	7
110	The effect of autoimmune blistering diseases on work productivity. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2018 , 32, 1959-1966	4.6	6
109	Prevalence and pathogenesis of osteopenia and osteoporosis in epidermolysis bullosa: An evidence-based review. <i>Experimental Dermatology</i> , 2019 , 28, 1122-1130	4	6
108	Advancement of women in dermatology. <i>International Journal of Dermatology</i> , 2011 , 50, 593-600	1.7	6
107	No evidence that human papillomavirus is responsible for the aggressive nature of recessive dystrophic epidermolysis bullosa-associated squamous cell carcinoma. <i>Journal of Investigative Dermatology</i> , 2010 , 130, 2853-5	4.3	6

106	Assessment of the quality of life of Egyptian and Tunisian autoimmune bullous diseases' patients using an Arabic version of the autoimmune bullous disease quality of life and the treatment of autoimmune bullous disease quality of life questionnaires. <i>Anais Brasileiros De Dermatologia</i> , 2019 , 94, 399-404	1.6	6
105	Chlorophyll-induced pseudoporphyria with ongoing photosensitivity after cessation - a case series of four patients. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2016 , 30, 1239-42	4.6	6
104	Autoimmune bullous diseases during pregnancy: Solving common and uncommon issues. <i>International Journal of Women's Dermatology</i> , 2019 , 5, 166-170	2	5
103	Virtual conferences of dermatology during the COVID-19 pandemic. <i>Dermatologic Therapy</i> , 2020 , 33, e13774	2.2	5
102	Inter-rater reliability of the BIOCHIP indirect immunofluorescence dermatology mosaic in bullous pemphigoid and pemphigus patients. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019 , 33, 2327-2333	4.6	5
101	Management of epidermolysis bullosa. <i>Expert Opinion on Orphan Drugs</i> , 2013 , 1, 279-293	1.1	5
100	Multidisciplinary care of epidermolysis bullosa during the COVID-19 pandemic-Consensus: Recommendations by an international panel of experts. <i>Journal of the American Academy of Dermatology</i> , 2020 , 83, 1222-1224	4.5	5
99	Financial burden of epidermolysis bullosa on patients in the United States. <i>Pediatric Dermatology</i> , 2020 , 37, 1198-1201	1.9	5
98	Outcomes and Predictors for Re-stenosis of Esophageal Stricture in Epidermolysis Bullosa: A Multicenter Cohort Study. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2020 , 71, 310-314	2.8	5
97	Intraepithelial autoimmune bullous dermatoses disease activity assessment and therapy. <i>Journal of the American Academy of Dermatology</i> , 2021 , 84, 1523-1537	4.5	5
96	Use of face masks in dermatology department during the COVID-19 outbreak. <i>Dermatologic Therapy</i> , 2020 , 33, e13521	2.2	4
95	Restructuring an academic dermatology practice during the COVID-19 pandemic. <i>Dermatologic Therapy</i> , 2020 , 33, e13684	2.2	4
94	Treatment concerns for bullous pemphigoid in the COVID-19 pandemic era. <i>Dermatologic Therapy</i> , 2020 , 33, e13956	2.2	4
93	An Atypical Localized Form of Hidradenitis Suppurativa of the Jawline and Neck Mimicking Severe Cystic Acne on Presentation. <i>Skin Appendage Disorders</i> , 2017 , 3, 215-218	1.4	4
92	Pigmented Hair-Thickening Fibers: A Camouflage Technique for Alopecia in Patients with Epidermolysis Bullosa. <i>Skin Appendage Disorders</i> , 2016 , 1, 153-5	1.4	4
91	Treatment of pemphigus vulgaris and pemphigus foliaceus. <i>Expert Review of Dermatology</i> , 2009 , 4, 469-481		4
90	Drug-related adverse effects of vismodegib and sonidegib for locally advanced or metastatic basal cell carcinoma. <i>Australasian Journal of Dermatology</i> , 2020 , 61, 176-177	1.3	4
89	Intraepithelial autoimmune blistering dermatoses: Clinical features and diagnosis. <i>Journal of the American Academy of Dermatology</i> , 2021 , 84, 1507-1519	4.5	4

88	Over-expression of stromal periostin correlates with poor prognosis of cutaneous squamous cell carcinomas. <i>Experimental Dermatology</i> , 2021 , 30, 698-704	4	4
87	Multiple cutaneous reticulohistiocytomas successfully treated with topical psoralen plus ultraviolet A therapy combined with intralesional injections of triamcinolone acetonide. <i>JAAD Case Reports</i> , 2015 , 1, 157-9	1.4	3
86	Sensitivity to change and correlation between the autoimmune bullous disease quality-of-life questionnaires ABQOL and TABQOL, and objective severity scores. <i>British Journal of Dermatology</i> , 2020 , 183, 944-945	4	3
85	Efficacy and tolerability of the investigational topical cream SD-101 (6% allantoin) in patients with epidermolysis bullosa: a phase 3, randomized, double-blind, vehicle-controlled trial (ESSENCE study). <i>Orphanet Journal of Rare Diseases</i> , 2020 , 15, 158	4.2	3
84	Disease-specific health related quality of life patient reported outcome measures in Genodermatoses: a systematic review and critical evaluation. <i>Orphanet Journal of Rare Diseases</i> , 2017 , 12, 189	4.2	3
83	Multiple sclerosis is the neurological disorder most highly associated with bullous pemphigoid. <i>British Journal of Dermatology</i> , 2017 , 176, 1428-1429	4	3
82	Topical Corticosteroids in Blistering Diseases 2018 , 91-100		3
81	COVID-19 and immunosuppressive therapy in dermatology. <i>Dermatologic Therapy</i> , 2020 , 33, e14140	2.2	3
80	Subepithelial autoimmune bullous dermatoses disease activity assessment and therapy. <i>Journal of the American Academy of Dermatology</i> , 2021 , 85, 18-27	4.5	3
79	What is the true mortality from pemphigus?. <i>British Journal of Dermatology</i> , 2016 , 174, 1185-6	4	3
78	Successful management of bullous pemphigoid with dimethyl fumarate therapy: A case report. <i>International Journal of Women's Dermatology</i> , 2019 , 5, 179-180	2	2
77	Retrospective evidence on outcomes and experiences of pregnancy and childbirth in epidermolysis bullosa in Australia and New Zealand. <i>International Journal of Women's Dermatology</i> , 2015 , 1, 26-30	2	2
76	Recessive dystrophic epidermolysis bullosa (RDEB) complicated by secondary hepatic amyloidosis. <i>JAAD Case Reports</i> , 2015 , 1, 337-9	1.4	2
75	Reply to: "COVID-19, syphilis, and biologic therapies for psoriasis and psoriatic arthritis: A word of caution". <i>Journal of the American Academy of Dermatology</i> , 2020 , 82, e215	4.5	2
74	Highly Resistant Acrodermatitis Continua of Hallopeau and Pustular Psoriasis. <i>Skin Appendage Disorders</i> , 2017 , 3, 179-181	1.4	2
73	Autoimmune Blistering Diseases and Corticosteroid Use: A Review of the Evidence 2015 , 459-468		2
72	Autoimmune diseases of the skin. <i>Immunology and Allergy Clinics of North America</i> , 2012 , 32, xiii-xiv	3.3	2
71	Dermatologic Clinics. Epidermolysis bullosa: part II--diagnosis and management. Preface. <i>Dermatologic Clinics</i> , 2010 , 28, xix	4.2	2

70	A complicated blistering disease case demonstrating the usefulness of immunoblotting and ELISA for the diagnosis of immunobullous diseases. <i>Australasian Journal of Dermatology</i> , 2006 , 47, A57-A57	1.3	2
69	Chinese version of the treatment of autoimmune bullous disease quality of life questionnaire: Reliability and validity. <i>Indian Journal of Dermatology, Venereology and Leprology</i> , 2018 , 84, 431-436	0.8	2
68	Dermatology and specialty rotations: COVID-19 may reemphasize the importance of internal medicine. <i>Dermatologic Therapy</i> , 2020 , 33, e13996	2.2	2
67	Wound closure in epidermolysis bullosa: data from the vehicle arm of the phase 3 ESSENCE Study. <i>Orphanet Journal of Rare Diseases</i> , 2020 , 15, 190	4.2	2
66	Role of music therapy in reducing the burden of dermatological diseases during COVID-19. <i>Dermatologic Therapy</i> , 2020 , 33, e14086	2.2	2
65	Heralding change within dermatology: Response of the International Journal of Women's Dermatology (IJWD) to the twin pandemic of racism. <i>International Journal of Women's Dermatology</i> , 2021 , 7, 125-126	2	2
64	Reply to: "Biologics for psoriasis during COVID-19 outbreak". <i>Journal of the American Academy of Dermatology</i> , 2020 , 82, e219	4.5	2
63	Authors' reply to the comment "Treatment considerations for patients with pemphigus during the COVID-19 pandemic". <i>Journal of the American Academy of Dermatology</i> , 2021 , 84, e61-e62	4.5	2
62	Is the Oral Disease Severity Score going to be useful for dermatologists when assessing pemphigus?. <i>British Journal of Dermatology</i> , 2018 , 179, 816-817	4	2
61	Assessing the quality of life in the families of patients with epidermolysis bullosa: The mothers as main caregivers.. <i>International Journal of Women's Dermatology</i> , 2021 , 7, 721-726	2	2
60	Patient-reported outcomes and quality of life in dominant dystrophic epidermolysis bullosa: A global cross-sectional survey. <i>Pediatric Dermatology</i> , 2021 , 38, 1198-1201	1.9	2
59	Conducting dermatology clinical trials during the COVID-19 pandemic. <i>Clinics in Dermatology</i> , 2021 , 39, 104-106	3	2
58	Pathogenesis and clinical features of alopecia in epidermolysis bullosa: A systematic review. <i>Pediatric Dermatology</i> , 2019 , 36, 430-436	1.9	1
57	Genetic screening for human leukocyte antigen alleles prior to carbamazepine treatment. <i>Journal of Clinical Neuroscience</i> , 2015 , 22, 1992-3	2.2	1
56	Successful dapsone therapy in inherited epidermolysis bullosa. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020 , 34, e333-e334	4.6	1
55	Bullous pemphigoid: therapeutic algorithm and practical management. <i>Expert Opinion on Orphan Drugs</i> , 2013 , 1, 405-412	1.1	1
54	Burden of disease scoring in epidermolysis bullosa. <i>British Journal of Dermatology</i> , 2015 , 173, 1357-8	4	1
53	Inherited epidermolysis bullosa. <i>Journal of the Egyptian Women's Dermatologic Society</i> , 2014 , 11, 1-13	0.3	1

52	The International Pemphigus and Pemphigoid Foundation. <i>Dermatologic Clinics</i> , 2011 , 29, 655-7	4.2	1
51	A comparison in real clinical practice of methyl aminolevulinate photodynamic therapy and surgery for small superficial basal cell carcinoma: 3-year recurrence rates and cosmetic outcomes. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2011 , 25, 117-8	4.6	1
50	Biological medication in atopic dermatitis.. <i>Expert Opinion on Biological Therapy</i> , 2022 , 1-7	5.4	1
49	Comparison of effectiveness of topical tacrolimus 0.1% vs topical halobetasol propionate 0.05% as an add-on to oral hydroxychloroquine in discoid lupus erythematosus. <i>Dermatologic Therapy</i> , 2021 , 34, e14675	2.2	1
48	Splicing of the cake can affect the severity of epidermolysis bullosa. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020 , 34, 1879-1880	4.6	1
47	Are biosimilars for pemphigus safe?. <i>Clinical and Experimental Dermatology</i> , 2021 , 46, 942-943	1.8	1
46	Cover image: Unpeeling the layers of harlequin ichthyosis. <i>British Journal of Dermatology</i> , 2016 , 174, 1160-1	4	1
45	Erythema Multiforme, Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis 2019 , 777-784		1
44	Epidermolysis Bullosa Patients' Perception of Surgical Wound and Scar Healing. <i>Dermatologic Surgery</i> , 2019 , 45, 280-289	1.7	1
43	Diagnostic Criteria and Phenotypes of Pemphigoid and the Association With Gliptins. <i>JAMA Dermatology</i> , 2019 , 155, 147-148	5.1	1
42	Novel diagnostic method to differentiate antilaminin-332 pemphigoid from other forms of pemphigoid. <i>British Journal of Dermatology</i> , 2020 , 182, 270-271	4	1
41	An analysis of the prevalence of osteoporosis and osteopenia in patients with epidermolysis bullosa: A cross-sectional study. <i>Experimental Dermatology</i> , 2021 , 30, 1675-1685	4	1
40	Bruton Tyrosine Kinase Inhibition and Its Role as an Emerging Treatment in Pemphigus. <i>Frontiers in Medicine</i> , 2021 , 8, 708071	4.9	1
39	The impact of gender in mentor-mentee success: Results from the Women's Dermatologic Society Mentorship Survey. <i>International Journal of Women's Dermatology</i> , 2021 , 7, 398-402	2	1
38	Osteoporosis and Psoriasis: A Literature Review.. <i>Clinical and Experimental Dermatology</i> , 2022 ,	1.8	1
37	Multiple milia formation in blistering diseases. <i>International Journal of Women's Dermatology</i> , 2020 , 6, 199-202	2	0
36	Training and Retaining Physician-Scientists in Dermatology: Australia.. <i>JID Innovations</i> , 2022 , 2, 100074		0
35	A comparison study of outcome measures for epidermolysis bullosa: Epidermolysis Bullosa Disease Activity and Scarring Index (EBDASI) and the Instrument for Scoring Clinical Outcomes of Research for Epidermolysis Bullosa (iscorEB). <i>JAAD International</i> , 2021 , 2, 134-152	0.9	0

34	Beyond the skin: disease parameters in pemphigus. <i>Italian Journal of Dermatology and Venereology</i> , 2021 , 156, 147-150	1.2	0
33	Impact of COVID-19 on inpatient dermatology consults in an Australian tertiary hospital. <i>Australasian Journal of Dermatology</i> , 2021 , 62, 427-428	1.3	0
32	Ectropion surgery might not be a long-term solution for harlequin ichthyosis. <i>Dermatologic Therapy</i> , 2021 , 34, e14646	2.2	0
31	Shedding light on the impact of hidradenitis suppurativa on women and their families: A focus of the .. <i>International Journal of Women's Dermatology</i> , 2021 , 7, 661-663	2	0
30	Embracing diversity in dermatology: Creation of a culture of inclusion in dermatologic publishing. <i>International Journal of Women's Dermatology</i> , 2021 , 7, 371-377	2	0
29	Allergic contact dermatitis to miconazole for nipple candidiasis.. <i>Contact Dermatitis</i> , 2022 ,	2.7	0
28	Mental health, insomnia and suicidal ideation during treatment with apremilast.. <i>Australasian Journal of Dermatology</i> , 2022 ,	1.3	0
27	Increasing prevalence but not incidence of psoriasis in the U.K. <i>British Journal of Dermatology</i> , 2017 , 176, 568-569	4	
26	Patients left behind: Rare dermatologic conditions miss the orphan drug development boom. <i>Journal of the American Academy of Dermatology</i> , 2019 , 81, 1025-1026	4.5	
25	Atopic Dermatitis Outcome Measures 2019 , 1-28		
24	The response of the Women's Dermatologic Society and the to the COVID-19 pandemic. <i>International Journal of Women's Dermatology</i> , 2020 , 6, 129-130	2	
23	Osteoporosis and bone health in autoimmune blistering skin disease-an evidenced based review. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020 , 34, 2745-2756	4.6	
22	Cover Image: The many faces of sarcoidosis. <i>British Journal of Dermatology</i> , 2016 , 175, 1111-1112	4	
21	Screening for infections prior to initiating immunosuppressive treatment for patients with autoimmune blistering diseases. <i>British Journal of Dermatology</i> , 2014 , 171, 1285-6	4	
20	Celebrating Outstanding Science at the European Academy of Dermatology and Venereology's 30th Anniversary Congress24-28		
19	Dermatoethics: Nepotism in Dermatology Residencies.. <i>Journal of the American Academy of Dermatology</i> , 2022 ,	4.5	
18	Atopic Dermatitis Outcome Measures 2019 , 1-28		
17	Diagnosis and Prevention of Bullous Diseases 2011 , 115-135		

16	Diagnosis and Prevention of Bullous Diseases 2011 , 53-73	
15	Mycobacterium chelonae infection mimicking Demodex folliculitis. <i>Clinical and Experimental Dermatology</i> , 2020 , 45, 469-470	1.8
14	A prickly souvenir from a hedgehog cañlinea manuum secondary to Trichophyton erinacei via international spread. <i>Clinical and Experimental Dermatology</i> , 2020 , 45, 459-461	1.8
13	Predatory journals: The silent intruder. <i>Dermatologic Therapy</i> , 2020 , 33, e13214	2.2
12	Managing epidermolysis bullosa during the coronavirus pandemic: Experience and ideals. <i>Clinics in Dermatology</i> , 2021 , 39, 369-373	3
11	What instruments should we add to our toolbox for measuring the severity and control of eczema?. <i>British Journal of Dermatology</i> , 2021 , 185, 13-14	4
10	Individual patients' risk factors impact guidelines for prophylactic agents used in pemphigus patients treated with rituximab. <i>Journal of the American Academy of Dermatology</i> , 2021 , 85, e47-e48	4.5
9	Pemphigus vulgaris accompanied with amyotrophic lateral sclerosis: a rare coincidence or pathogenic relationship?. <i>European Journal of Dermatology</i> , 2019 , 29, 435-436	0.8
8	Cardiac Involvement in Epidermolysis Bullosa 2021 , 33-48	
7	The Importance of Cardiac Assessment in the Era of Biologic Therapies for Psoriasis 2021 , 419-430	
6	Hindi translation and validation of quality of life score in Indian patients with epidermolysis bullosa; and its correlation with the clinical severity assessment scores: A cross-sectional study. <i>Indian Journal of Dermatology, Venereology and Leprology</i> , 2021 , 1-7	0.8
5	State-of-the-art review of human autoimmune blistering diseases (AIBD). <i>Veterinary Dermatology</i> , 2021 , 32, 524-e145	1.8
4	Evaluating diversity in Clinics in Dermatology: Diversity in clinics in dermatology: M. Sun et'ál.. <i>Clinics in Dermatology</i> , 2021 , 39, 1064-1066	3
3	Sebaceous cell carcinoma presenting as an ocular Marjolin ulcer following immunosuppression for a chemical burn from a common alkaline cleaning agent.. <i>Canadian Journal of Ophthalmology</i> , 2022 ,	1.4
2	Assessment of published literature regarding skin of color in Pediatric Dermatology.. <i>Pediatric Dermatology</i> , 2021 , 38, 1604-1605	1.9
1	How do experts treat patients with bullous pemphigoid around the world? An international survey.. <i>JID Innovations</i> , 2022 , 100129	